Evidence map›Paper›PMID 31604081›Full record

Trial reportJournal of hepatology2020

Integrating HCV testing with HIV programs improves hepatitis C outcomes in people who inject drugs: A cluster-randomized trial.

Sunil Suhas Solomon, Thomas C Quinn, Suniti Solomon, Allison M McFall, Aylur K Srikrishnan, Vinita Verma, Muniratnam S Kumar, Oliver Laeyendecker, David D Celentano, Syed H Iqbal and 7 more

Registry-linked trialOpen access · greenAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01686750 (A Cluster Randomized Trial of Integrated Care Centers to Improve Access to HIV Prevention, Testing, and Treatment Services Among High-Risk Vulnerable Populations in India), which is not on this map. Cited by 28 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 5 pooled it
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01686750 nacompletednot on this map

A Cluster Randomized Trial of Integrated Care Centers to Improve Access to HIV Prevention, Testing, and Treatment Services Among High-Risk Vulnerable Populations in India

TypeinterventionalSponsorJohns Hopkins UniversityRan2012 to 2017Enrolled21,726ConditionsHIV InfectionArmsIntegrated care centers
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 5 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 2 countries.

Sunil Suhas SolomonDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: sss@jhmi.edu.
Thomas C QuinnDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Suniti SolomonYR Gaitonde Centre for AIDS Research and Education (YRGCARE), Chennai, India.
Allison M McFallDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Aylur K SrikrishnanYR Gaitonde Centre for AIDS Research and Education (YRGCARE), Chennai, India.
Vinita VermaNational AIDS Control Organisation, Ministry of Health and Family Welfare, New Delhi, India.
Muniratnam S KumarYR Gaitonde Centre for AIDS Research and Education (YRGCARE), Chennai, India.
Oliver LaeyendeckerDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
David D CelentanoDepartment of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
Syed H IqbalYR Gaitonde Centre for AIDS Research and Education (YRGCARE), Chennai, India.
Santhanam AnandYR Gaitonde Centre for AIDS Research and Education (YRGCARE), Chennai, India.
Canjeevaram K VasudevanYR Gaitonde Centre for AIDS Research and Education (YRGCARE), Chennai, India.
Shanmugam SaravananYR Gaitonde Centre for AIDS Research and Education (YRGCARE), Chennai, India.
David L ThomasDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kuldeep Singh SachdevaNational AIDS Control Organisation, Ministry of Health and Family Welfare, New Delhi, India.
Gregory M LucasDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Shruti H MehtaDepartment of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA.
Johns Hopkins University · USYR Gaitonde Centre for AIDS Research and Education · INNational Institutes of Health · US

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUSAN JANET LITTLE · 1994 to 2026
$78.4M
Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
Strategies to improve the HIV care continuum among key populations in IndiaR01DA041034 · NIDA · JOHNS HOPKINS UNIVERSITY · PI LUCAS, GREGORY M, MEHTA, SHRUTI H · 2015 to 2021
$6.7M
Integrated Care Clinics for IDUs in India: a cluster randomized trialR01DA032059 · NIDA · JOHNS HOPKINS UNIVERSITY · PI LUCAS, GREGORY M, MEHTA, SHRUTI H · 2011 to 2015
$6.3M
Johns Hopkins HIV Epidemiology and Prevention Sciences Training ProgramT32AI102623 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Shruti H Mehta · 2013 to 2026
$5.3M
Preventing HIV Infection Among MSM in Southern IndiaR01MH089266 · NIMH · JOHNS HOPKINS UNIVERSITY · PI CELENTANO, DAVID D. · 2010 to 2015
$2.9M
Reaching the hardest of the hard-to-reachDP2DA040244 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SOLOMON, SUNIL SUHAS · 2016 to 2023
$2.8M
Treatment outcomes and comorbidity in HIV-infected IDUK24DA035684 · NIDA · JOHNS HOPKINS UNIVERSITY · PI LUCAS, GREGORY M · 2014 to 2024
$1.5M
Investigating the Potential of Respondent-Driven Sampling to Reach Undiagnosed, Out-of-Care HIV-infected People Who Inject DrugsF31DA044046 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MCFALL, ALLISON MARIE · 2017 to 2018
$78k
NCATS NIH HHS UL1 TR001442NIAID NIH HHS P30 AI036214NIAID NIH HHS P30 AI094189NIAID NIH HHS T32 AI102623NIDA NIH HHS DP2 DA040244NIDA NIH HHS F31 DA044046NIDA NIH HHS K24 DA035684NIDA NIH HHS R01 DA032059NIDA NIH HHS R01 DA041034NIMH NIH HHS R01 MH089266
6 · The paper itself

Abstract

BACKGROUND &

aimsThere have been calls to integrate HCV testing into existing services, including harm reduction and HIV prevention and treatment, but there are few empirical trials to date. We evaluated the impact of integrating HCV testing/education into integrated care centers (ICCs) delivering HIV services to people who inject drugs (PWID) across India, using a cluster-randomized trial.

methodsWe compared ICCs with usual care in the PWID stratum (12 sites) of a 22-site cluster-randomized trial. In 6 sites, ICCs delivering HIV testing, harm reduction, other preventive services and linkage to HIV treatment were scaled from opioid agonist therapy centers and operated for 2 years. On-site rapid HCV antibody testing was integrated after 1 year. To assess impact, we conducted baseline and evaluation surveys using respondent-driven sampling (RDS) across the 12 sites (n = 11,993 recruited at baseline; n = 11,721 recruited at evaluation). The primary outcome was population-level self-reported HCV testing history.

resultsAt evaluation, HCV antibody prevalence ranged from 7.2-76.6%. Across 6 ICCs, 5,263 ICC clients underwent HCV testing, of whom 2,278 were newly diagnosed. At evaluation, PWID in ICC clusters were 4-fold more likely to report being tested for HCV than in usual care clusters, adjusting for baseline testing (adjusted prevalence ratio [aPR] 3.69; 95% CI 1.34-10.2). PWID in ICC clusters were also 7-fold more likely to be aware of their HCV status (aPR 7.11; 95% CI 1.14-44.3) and significantly more likely to initiate treatment (aPR 9.86; 95% CI 1.52-63.8).

conclusionsWe provide among the first empirical data supporting the integration of HCV testing into HIV/harm reduction services. To achieve elimination targets, programs will need to scale-up such venues to deliver comprehensive HCV services. CLINICALTRIALS. GOV IDENTIFIER: NCT01686750. LAY SUMMARY: Delivering hepatitis C virus (HCV) testing to people who inject drugs (PWID) in places where they also have access to HIV prevention and treatment services is an effective way to improve uptake of HCV testing among communities of PWID. To achieve the World Health Organization's ambitious elimination targets, integrated programs will need to be scaled up to deliver comprehensive HCV services.

Indexed as

HIVAdultAIDS-Related Opportunistic InfectionsCluster AnalysisComorbidityCross-Sectional StudiesDelivery of Health Care, IntegratedFemaleHarm ReductionHepacivirusHepatitis CHepatitis C AntibodiesHumansIndiaMalePrevalenceHepatitis C AntibodiesCluster-randomised trialHCVHepatitis C virusHIVIndiaIntegrated carePeople who inject drugsPWID

Identifiers

PMID31604081
PMCPMC7173404
OpenAlexW2979825755

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.